Tagged with Canada

Canada Clint Sharples, CEO of Heritage Cannabis, gives a potted history of the medical cannabis industry in Canada, its current legal status, provincial variations in patient registrations, financial performance, the impact of COVID-19, and where the field is headed for the future.   The cannabis plant has been used as a…

UK When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left behind in terms of alignment with the world’s top regulatory bodies. Perhaps cognizant of this, the UK regulatory agency for…

USA Market access and pricing expert Barbara Jaszewski outlines the issues inherent in the USA importing drugs from Canada and why such proposals retain political capital despite massive and proven flaws.   Drug importation is a curious “zombie” proposal that never seems to die Donald Trump and Bernie Sanders have one…

Canada As the only country in the world to boast a universal healthcare system that does not cover prescription drugs, Canada has been struggling with the concept of ‘national pharmacare’ for a number of years now, with fierce advocates on both sides of the debate.   Canada [has] some of the…

Canada Up-to-date data and infographics on the Canadian pharma market including an overview of market dynamics, pharmaceutical and biologics spending, production costs, and pricing changes.   Canada pharma data overview. Made with Visme Infographic Maker   Pharmaceutical spending as a percentage of GDP in Canada (international comparison). Made with Visme Infographic Maker  …

Canada The latest news from Canadian pharma including deals for J&J’s and Novavax’s COVID-19 vaccines, an abrupt end to Canada’s participation in CanSino Biologics’ clinical trials the country’s first medical cannabis clinical trial, and Innovative Medicines Canada’s top priorities.   Canada signs deals for J&J, Novavax COVID vaccines https://pharmaphorum.com/news/canada-signs-deals-for-jj-novavax-COVID-vaccines/ Under the…

Pricing Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for withdrawing drug approval applications, cutting jobs, or delaying launches, claiming the new pricing regulations will substantially reduce revenues.    The…

Canada Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies.   We’re at the advent of a potential landmark…

Canada John L. Wallace of Antibe Therapeutics highlights how Canadian innovation stands to put the country at the forefront of the next wave of global biopharmaceutical R&D. BlueRock Therapeutics, a promising North American start-up with a new Parkinson’s disease drug, was recently sold to Germany’s Bayer at a $1 billion valuation.…

Canada Pamela Fralick of Innovative Medicines Canada (IMC) advocates for a collaborative multi-stakeholder approach to better tackle rare diseases in Canada.   Especially in smaller provinces, it’s virtually impossible to predictably manage the affordability and accessibility of drugs necessary to treat rare disease Around the world, rare diseases are becoming easier…

Canada Marina Vasiliou took the reins as managing director of Biogen Canada in November 2017 after a long and varied career at MSD in a wide variety of geographies.   Canada’s biggest strengths are its diversity and openness—whether that is in health sciences or the culture itself Marina Vasiliou, Biogen Vasiliou…

Canada Diabetes Canada’s Jan Hux outlines how her organization has been able to shift from small, local programs to driving change at a much larger level via a ‘collective impact’ approach.   When I encountered the concept of collective impact in the Stanford Social Innovation Review, I realized the possibilities lay…